1.Bhorade, SM, Christensen, J, Pohlman, AS, Arnow, PM, Hall, JB. The incidence of and clinical variables associated with vancomycin-resistant enterococcal colonization in mechanically ventilated patients. Chest 1999;115:1085–1091.
2.Linden, PKet al.Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-sus-ceptible E. faecium. Clin Infect Dis 1996;22:663–670.
3.Stosor, Vet al.Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch Intern Med 1998;158:522–527.
4.Edmond, MBet al.Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996;23:1234–1239.
5.Carmeli, Yet al.Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med 2002;162:2223–2228.
6.Lucas, GMet al.Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis 1998;26:1127–1133.
7.National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470–485.
8.Saigado, CD, Farr, BM. Outcomes associated with vancomycin-resistant enterococci: a meta-analysis. Infect Control Hosp Epidemiol 2003;24:690–698.
9.CA, DiazGranadoset al.Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005;41:327–333.
10.Peset, Vet al.Epidemiological, microbiological, clinical, and prognostic factors of bacteremia caused by high-level vancomycin-resistant Enterococcus species. Eur J Clin Microbiol Infect Dis 2000;19:742–749.
11.Garbutt, JMet al.Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clin Infect Dis 2000;30:466–472.
12.Vergis, ENet al.Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia, a prospective multicenter study. Ann Intern Med 2001;135:484–492.
13.Tornieporth, NGet al.Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1996;23:767–772.
14.Lautenbach, E, Bilker, WB, Brennan, PJ. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999;20:318–323.
15.Bonten, MJet al.The role of “colonization pressure” in the spread of vancomycin-resistant enterococci: an important infection control variable. Arch Intern Med 1998;158:1127–1132.
16.Lucus, GM, Lechtzin, N, Puryear, DW, Yau, LL, Flexner, CW, Moore, RD. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis 1998;26:1127–1133.
17.Zaas, AKet al.Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. Clin Infect Dis 2002;35:1139–1146.
18.Shay, DKet al.Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect 1995;172:993–1000.
19.Furtado, GHet al.Risk factors for vancomycin-resistant Enterococcus faecalis bacteremia in hospitalized patients: an analysis of two case-control studies. Am J Infect Control 2006;34:447–451.
20.Montecalvo, MAet al.Outbreak of vancomycin-, ampicillin-, and ami-noglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother 1994;38:1363–1367.
21.Roghmann, MCet al.Clostridium difficile infection is a risk factor for bacteremia due to vancomycin-resistant enterococci (VRE) in VRE-col-onized patients with acute leukemia. Clin Infect Dis 1997;25:1056–1059.
22.Matar, MJ, Tarrand, J, Raad, I, Rolston, KVI. Colonization and infection with vancomycin-resistant Enterococcus among patients with cancer. Am J Infect Control 2006;34:534–536.
23.Kapur, Det al.Incidence and outcome of vancomycin-resistant enterococcal bacteremia following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2000;25:147–152.
24.Tenover, FCet al.Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995;33:2233–2239.
25.Weinstock, DMet al.Colonization, bloodstream infection, and mortality caused by vancomycin-resistant Enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 2007;13:615–621.
26.Patel, Ret al.Natural history of vancomycin-resistant enterococcal colonization in liver and kidney transplant recipients. Liver Transpl 2001;7:27–31.
27.Brennen, C, Wagener, MM, Muder, RR. Vancomycin-resistant Enterococcus faecium in a long-term care facility, J Am Geriatr Soc 1998;46:157–160.
28.Bakir, M, Bova, JL, Newell, KA, Micael, MI, Buell, JF, Arnow, PM. Epidemiology and clinical consequences of vancomycin-resistant enterococci in liver transplant patients. Transplantation 2001;72:1032–1037.
29.McNeil, SA, Malani, PN, Chenoweth, CE, et al.Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis 2006;42:195–203.
30.Mainous, MR, Lipsett, PA, O'Brien, M. Enterococcal bacteremia in the surgical intensive care unit. Does vancomycin resistance affect mortality? The Johns Hopkins SICU Study Group. Arch Surg 1997;132:76–81.
31.Carmeli, Y, Samore, MH, Huskins, C. The association between antecedent vancomycin treatment and hospital-acquired vancomycin-resistant enterococci: a meta-analysis. Arch Intern Med 1999;159:2461–2468.
32.Huh, JY, Lee, WG, Jin, HY. Molecular characterization of vancomycin-resistant enterococci from clinical and surveillance specimens. Infect Control Hosp Epidemiol 2006;27:1076–1080.
33.Henning, KJet al.Vancomycin-resistant Enterococcus faecium on a pediatric oncology ward: duration of stool shedding and incidence of clinical infection. Pediatr Infect Dis J 1996;15:848–854.
34.LeDell, Ket al.SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003;24:639–641.
35.Siegel, JD, Rhinehart, E, Jackson, M, Chiarello, L, and the Healthcare Infection Control Practices Advisory Committee, Management of Multi-drug-Resistant Organisms in Healthcare Settings. 2006. Center for Disease Control and Prevention. Available at: http://www.cdc.gov/ncidod/dhqp/pdf/ar/mdroGuideline2006.pdf. Accessed October 31, 2007.